Dr Reddy's Shares Drop 7% as Quality Issues Delay Weight-Loss Drug Launch
Source: Economictimes
Shares of Dr Reddy’s Laboratories witnessed a sharp decline after the company paused commercial supplies of its semaglutide product. The delay stems from quality concerns regarding the active pharmaceutical ingredient (API) used in the drug.
- ▸Dr Reddy's has paused the supply of its semaglutide drug due to API quality concerns.
- ▸The stock price fell by 7% as investors reacted to the potential delay in market entry.
- ▸The company maintains that patient safety and regulatory filings are not at risk.
- ▸An internal investigation is underway to fix the production issue and resume supplies.
- ✓Dr Reddy's has paused the supply of its semaglutide drug due to API quality concerns.
- ✓The stock price fell by 7% as investors reacted to the potential delay in market entry.
- ✓The company maintains that patient safety and regulatory filings are not at risk.
- ✓An internal investigation is underway to fix the production issue and resume supplies.
Investors in Dr Reddy’s Laboratories faced a volatile trading session on Thursday as the company’s stock price tumbled by approximately 7%. The sell-off was triggered by an official announcement regarding the delay in the commercial rollout of its semaglutide product, a highly anticipated medication used in the treatment of type 2 diabetes and weight management.
The Root of the Delay
The pharmaceutical major confirmed that the delay is linked to a quality issue involving the Active Pharmaceutical Ingredient (API). The API is the primary biological component responsible for the drug's effect. While the company has not specified the exact nature of the defect, it has initiated a comprehensive investigation to identify the root cause and rectify the production line.
Impact on Patients and Regulatory Status
In a move to reassure stakeholders, Dr Reddy’s clarified that this development does not compromise patient safety, as the affected batches have not reached the retail market. Furthermore, the company stated that its existing regulatory filings remain unaffected. The primary impact is currently limited to the timeline of commercial availability and the immediate sentiment of the stock market.
Market Reaction and Outlook
The 7% slide reflects investor anxiety over the competitive landscape of the weight-loss drug market. Semaglutide is a high-demand molecule globally, and any delay in its supply chain could potentially allow competitors to gain a larger market share. Analysts are closely watching how quickly the company can restore its supply chain and whether this issue will lead to any long-term capital expenditure adjustments.
- The stock hit a session low following the news.
- Investigation is ongoing to restore supplies.
- No impact reported on other product portfolios.
This article is for informational purposes only and does not constitute financial or investment advice.
Some listings may be sponsored. Mutual fund data is from AMFI and for information only — funds are subject to market risks. Review terms & suitability before investing. Not investment advice.
Frequently Asked Questions
Why did Dr Reddy's share price fall today?
The shares fell by 7% after the company announced a delay in the commercial supply of its semaglutide product due to quality issues with the raw materials (API).
Is the drug semaglutide safe for current users?
Yes, the company stated that patient safety is unaffected as the quality issue was identified before the commercial supplies reached the public.
What is semaglutide used for?
Semaglutide is a medication primarily used for managing type 2 diabetes and is also widely used for weight loss treatment.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about Stock Market
Apollo Micro Systems Eyes Premier Explosives Acquisition for Defence Sector Expansion
Apollo Micro Systems' shares saw a slight uptick following reports of a potential acquisition of Premier Explosives. The deal, estimated between ₹2,300 crore and ₹2,500 crore, aims to bolster Apollo's position in the defence manufacturing supply chain amidst increasing government focus and investor interest in the sector.
Pfizer Faces Dual Crisis: Stock Performance Slumps as Iconic Headquarters Decays
Pharmaceutical giant Pfizer is grappling with a significant decline in stock value alongside the physical deterioration of its former landmark building. This trend highlights the company's struggle to maintain its pandemic-era momentum in a post-COVID market.
Global Healthcare Dividends: Why Pfizer Misses the Cut for Top Income Stocks
While healthcare stocks are often seen as safe havens for dividend seekers, recent market shifts have changed the outlook for major players. Experts are highlighting two specific healthcare stocks for their consistent payouts, while cautioning that former favorite Pfizer may no longer be the best choice for income-focused investors.
Related Stories
ಡಾ. ರೆಡ್ಡೀಸ್ ಷೇರುಗಳು 7% ಕುಸಿತ; ಗುಣಮಟ್ಟದ ಸಮಸ್ಯೆಯಿಂದ ತೂಕ ಇಳಿಸುವ ಔಷಧ ಬಿಡುಗಡೆ ವಿಳಂಬ
ಡಾ. ರೆಡ್ಡೀಸ್ ಲ್ಯಾಬೊರೇಟರೀಸ್ ತನ್ನ ಸೆಮಾಗ್ಲುಟೈಡ್ ಉತ್ಪನ್ನದ ವಾಣಿಜ್ಯ ಪೂರೈಕೆಯನ್ನು ಸ್ಥಗಿತಗೊಳಿಸಿದ ನಂತರ ಕಂಪನಿಯ ಷೇರುಗಳಲ್ಲಿ ತೀವ್ರ ಕುಸಿತ ಕಂಡುಬಂದಿದೆ. ಔಷಧದಲ್ಲಿ ಬಳಸಲಾಗುವ ಆಕ್ಟಿವ್ ಫಾರ್ಮಾಸ್ಯುಟಿಕಲ್ ಇಂಗ್ರಿಡಿಯಂಟ್ (API) ಗುಣಮಟ್ಟದ ಕಾಳಜಿಯಿಂದಾಗಿ ಈ ವಿಳಂಬ ಉಂಟಾಗಿದೆ.
डॉ. रेड्डीज के शेयरों में 7% की गिरावट; क्वालिटी संबंधी समस्याओं के कारण वजन घटाने वाली दवा की लॉन्चिंग में देरी
डॉ. रेड्डीज लैबोरेटरीज के शेयरों में भारी गिरावट देखी गई क्योंकि कंपनी ने अपने सेमाग्लूटाइड उत्पाद की कमर्शियल सप्लाई रोक दी है। यह देरी दवा में इस्तेमाल होने वाले एक्टिव फार्मास्युटिकल इंग्रीडिएंट (API) से संबंधित गुणवत्ता संबंधी चिंताओं के कारण हुई है।
डॉ. रेड्डीजच्या शेअर्समध्ये 7% घसरण; गुणवत्ता समस्यांमुळे वजन कमी करण्याच्या औषधाच्या लाँचला विलंब
डॉ. रेड्डीज लॅबोरेटरीजने त्यांच्या सेमाग्लूटाइड उत्पादनाचा व्यावसायिक पुरवठा थांबवल्यानंतर कंपनीच्या शेअर्समध्ये मोठी घसरण झाली. औषधामध्ये वापरल्या जाणाऱ्या ॲक्टिव्ह फार्मास्युटिकल इंग्रीडिएंट (API) च्या गुणवत्तेबाबतच्या चिंतेमुळे हा विलंब झाला आहे.
डॉ रेड्डीज के शेयर 7% गिरे, गुणवत्ता संबंधी समस्याओं के कारण वज़न घटाने वाली दवा के लॉन्च में देरी
डॉ रेड्डीज लेबोरेटरीज के शेयर में तेज गिरावट देखी गई, क्योंकि कंपनी ने अपने सेमाग्लूटाइड उत्पाद की वाणिज्यिक आपूर्ति रोक दी है। यह देरी दवा में इस्तेमाल होने वाले सक्रिय दवा घटक (API) से संबंधित गुणवत्ता संबंधी चिंताओं के कारण हुई है।